Molecular Response enables pharmaceutical partners to realize efficiencies in drug development through use of clinically proven molecular markers. We provide comprehensive clinical trial support services from trial-site sample collection to full clinical analysis.
Molecular Response routinely apply available standard of care clinical information with clinically valid, novel and proprietary molecular markers to develop high-value knowledge for existing pharmaceutical development processes and programs; the result reduces risk of development and allows for the most informed decision-making possible.
Molecular Response uses only validated methodologies and proven technology platforms to test precious clinical specimens from patients treated with investigational agents. And to fast-track therapeutic approval, we translate biomarker tests into diagnostic assays regulated as Laboratory Developed tests (LDT) under CLIA guidelines or In Vitro Diagnostics (IVD) through the FDA.